Kadmon Stock Forecast, Price & News

-0.19 (-4.55 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.89 million shs
Average Volume3.02 million shs
Market Capitalization$686.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.

Kadmon logo

About Kadmon

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.80 out of 5 stars

Medical Sector

205th out of 2,097 stocks

Pharmaceutical Preparations Industry

96th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kadmon (NASDAQ:KDMN) Frequently Asked Questions

Is Kadmon a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kadmon stock.
View analyst ratings for Kadmon
or view top-rated stocks.

What stocks does MarketBeat like better than Kadmon?

Wall Street analysts have given Kadmon a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kadmon wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Kadmon

How were Kadmon's earnings last quarter?

Kadmon Holdings, Inc. (NASDAQ:KDMN) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm earned $0.56 million during the quarter, compared to the consensus estimate of $0.72 million. Kadmon had a negative net margin of 5,103.69% and a negative trailing twelve-month return on equity of 142.70%.
View Kadmon's earnings history

How has Kadmon's stock price been impacted by COVID-19?

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KDMN stock has increased by 14.7% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KDMN?

6 equities research analysts have issued 1-year target prices for Kadmon's shares. Their forecasts range from $8.00 to $20.00. On average, they expect Kadmon's stock price to reach $12.00 in the next year. This suggests a possible upside of 200.8% from the stock's current price.
View analysts' price targets for Kadmon
or view top-rated stocks among Wall Street analysts.

Who are Kadmon's key executives?

Kadmon's management team includes the following people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 68, Pay $1.22M)
  • Mr. Steven Meehan, Exec. VP & CFO (Age 56, Pay $830k)
  • Mr. Gregory S. Moss Esq., Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 37, Pay $709.88k)
  • Mr. Kyle Carver, Sr. VP, Chief Accounting Officer & Controller
  • Ellen Cavaleri, Director of Investor Relations
  • Dr. John L. Ryan, Exec. VP and Exec. Medical Director of Clinical & Regulatory Devel. (Age 78)
  • Mr. Sanjay Aggarwal, Sr. VP of Clinical Devel.
  • Ms. Haya Taitel M.S., R.Ph., Sr. VP & Chief Commercial Officer
  • Dr. Simon Cooper, Sr. VP & Chief Medical Officer

Who are some of Kadmon's key competitors?

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the NASDAQ under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.45%), Point72 Asset Management L.P. (6.85%), Laurion Capital Management LP (3.78%), Great Point Partners LLC (2.76%), Morgan Stanley (2.37%) and Mizuho Markets Americas LLC (2.20%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc.
View institutional ownership trends for Kadmon

Which institutional investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Woodline Partners LP, Eversept Partners LP, Goldman Sachs Group Inc., Credit Suisse AG, Maverick Capital Ltd., Squarepoint Ops LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Kadmon
or view top insider-selling stocks.

Which institutional investors are buying Kadmon stock?

KDMN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Mizuho Markets Americas LLC, Laurion Capital Management LP, Morgan Stanley, BlackRock Inc., Schonfeld Strategic Advisors LLC, Citigroup Inc., and Nomura Holdings Inc.. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc.
View insider buying and selling activity for Kadmon
or or view top insider-buying stocks.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $3.99.

How much money does Kadmon make?

Kadmon has a market capitalization of $686.18 million and generates $8.29 million in revenue each year. The company earns $-108,910,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Kadmon have?

Kadmon employs 127 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is

Where are Kadmon's headquarters?

Kadmon is headquartered at 450 East 29th Street, New York NY, 10016.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833 900 5366 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.